Biotech Values

[DewDiligence]

It’s excellent news for MNTA investors that an FDA staffer cites MNTA’s generic Lovenox as the impetus for the FDA’s going “one step further” than the EMA is enabling biogenerics. This is consistent with Craig Wheeler’s claim that the FDA’s requirements for generic Lovenox were essentially crafted by MNTA itself.